Zura Bio’s (ZURA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Zura Bio (NASDAQ:ZURA) in a report published on Friday, Benzinga reports.

Several other brokerages have also recently commented on ZURA. HC Wainwright assumed coverage on shares of Zura Bio in a research note on Thursday, September 5th. They issued a “neutral” rating and a $5.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th.

Zura Bio Stock Up 0.6 %

NASDAQ ZURA opened at $4.92 on Friday. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The business has a 50-day moving average price of $3.92 and a 200-day moving average price of $3.96.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Sell-side analysts forecast that Zura Bio will post -0.47 EPS for the current year.

Insider Buying and Selling at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 15.80% of the stock is owned by company insiders.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new position in Zura Bio during the second quarter valued at $43,000. Renaissance Technologies LLC grew its holdings in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Zura Bio in the 3rd quarter worth about $62,000. Forefront Analytics LLC lifted its stake in Zura Bio by 22.1% in the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after purchasing an additional 7,531 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Zura Bio by 15.8% during the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares during the period. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.